Introduction {#sec1_1}
============

Lymphoma constitutes approximately 7% of all urogenital neoplasm \[[@B1]\]. The most frequent finding is of bladder involvement secondary to nodal disease \[[@B2]\]. Although cases of urethral lymphoma have been reported, the majority involve tumors arising in mucosa-associated lymphoid tissue (MALT) \[[@B3], [@B4]\]. Primary tumors arising from the urethra remain case reportable. Of the cases of primary urethral lymphoma that have been described, 19 cases have been reported in female patients and 7 cases in men, 1 of which was associated with HIV infection \[[@B1], [@B5]--[@B7]\]. Limited clinical experience has resulted in uncertainty concerning the most appropriate form of therapy for this malignancy.

Case {#sec1_2}
====

In February 2007, a 30-year-old woman presented to the gynecology clinic with a small painless mass at the urethral orifice. She underwent surgical excision of the lesion and histopathology revealed a mixture of acute and chronic inflammation consistent with urethral carbuncle. Two months later she presented with a hyperemic small swelling at the site of the excision. She underwent re-excision; and a mass from the urethral mucosa was biopsied. Pathologic examination of the specimen revealed a diffuse monotonous proliferation of malignant lymphoid cells of mostly large cell size; some of which are medium size and have a monocytoid appearance. The urethral mucosa above the infiltrate is focally infiltrated by malignant lymphoid cells (**fig. [1](#F1){ref-type="fig"}**, **fig. [2](#F2){ref-type="fig"}**). The deep component of the tumor infiltrates the glandular epithelium of the urethra (lymphoepithelial lesion); a feature strongly suggestive of MALT lymphoma (**fig. [3](#F3){ref-type="fig"}**). Immunohistochemistry for cytokeratin highlights these lesions (**fig. [4](#F4){ref-type="fig"}**, **fig. [5](#F5){ref-type="fig"}**). Immunocytochemistry studies demonstrated that the tumor cells have a strong positive reaction to CD45 (leukocytic common antigen, LCA) and CD20 (**fig. [6](#F6){ref-type="fig"}**).

For staging workup she underwent chest, abdomen and pelvis CT which revealed no mediastinal lymphadenopathy, no lung focal lesion, a 3-mm cystic focus on the right lobe of the liver, normal spleen, pancreas and kidney, and no abdominal or pelvic lymphadenopathy. There is a slight apparent localized thickening of the bladder neck. MRI of the hepatic lesion revealed a simple benign cyst. Blood workup including LDH, ESR, β~2~ microglobulin, HIV, hepatitis and STD profile was done and all were normal. Bone marrow examination was negative. Upper gastrointestinal endoscopy did not reveal any MALT-associated lesions. Therefore, the final diagnosis was non-Hodgkin\'s lymphoma of female urethra, diffuse large B-cell, possibly transformed from MALT lymphoma, stage IE according to Cotswolds modification of the Ann Arbor staging system.

The patient was offered localized radiotherapy. She refused this modality after being counseled about the possible side effects including the high possibility of infertility. Accordingly, we offered her chemotherapy (R-CHOP regimen including, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone). The patient underwent staging reassessment with CT scan and cytoscopy after 4 chemotherapy cycles. Multiple biopsies revealed a complete remission. A total of 6 cycles of CHOP and 8 cycles of rituximab were completed. Patient follow-up was done 3 months later with CT scan and cytoscopy confirming the complete remission. The patient has been free of disease for 4 years.

Discussion {#sec1_3}
==========

Caruncles are the most common lesions of the female urethra; they are inflammatory nodules that arise at the urethral meatus in postmenopausal women \[[@B8]\]. Urethral caruncles usually arise from the posterior lip of the urethral meatus. The lesion is considered to be neither neoplastic nor preneoplastic, but probably results from local trauma or inflammation. However, carcinoma (1.6%) and Bowen\'s disease (0.8%) are extremely rare and have been noted in 2.4% of patients with a clinical diagnosis of urethral caruncle. Macroscopically, a caruncle is a nodular or pedunculated erythematous lesion that may bleed easily.

Lymphoma of the female urethra, on the other hand, is an exceedingly rare condition. The literature describes only 27 cases (19 of them were female and 8 were male; **table [1](#T1){ref-type="table"}**). All were non-Hodgkin\'s lymphoma \[[@B9]--[@B13]\]. The age distribution ranged from 31 to 90 years with a mean of 67 years. The most common reported complaints were polyp, dysuria, urethral mass, irregular vaginal bleeding, gross hematuria, pain, urinary retention, carbuncle, and genital itching \[[@B13]--[@B17]\].

Four cases have been reported as having a painless mass at the urethral meatus resembling a caruncle as in our own case \[[@B9], [@B10]\]. Two cases were treated with radiotherapy, one case was treated with excision, and the last was treated palliatively. Our case is the first urethral lymphoma case treated with chemotherapy (CHOP-R). Another male urethral case was treated with CHOP without rituximab. In that described case of primary lymphoma of a male urethra, the patient remained alive and in complete remission 2 years after surgical removal and 6 courses of CHOP chemotherapy. It has been reported that prognosis for short-term local control of the urethral tumor with chemotherapy is excellent; recent cases show a short-term control rate of 100% \[[@B18]\].

Conclusion {#sec1_4}
==========

There is no universally accepted treatment scheme for these tumors. Although, several authors have reported reasonable success using excision, radiotherapy, chemotherapy, or combinations. Although the number of cases reported was very small and the follow-up period was short in all cases, local therapy including excision or external beam radiation with/without chemotherapy showed a good outcome in patients with local or locally invasive tumor. However, patients with disseminated disease showed a poor prognosis regardless of the kind of initial treatment. Accordingly, in patients with unfavorable histology or disseminated disease, early intensive chemotherapy is recommended. Use of the chemotherapy regimen CHOP-R seems to be a reasonable treatment option. For patients without bulky disease, 6--8 cycles of CHOP-R without radiotherapy have been shown to be an equally effective alternative as reported in our case \[[@B19]\]. Therefore, we recommend that any caruncle-like lesion should be evaluated with a suspicion of a malignant tumor unless proved otherwise.

![Diffuse monotonous proliferation of malignant lymphoid cells, the urethral mucosa above the infiltrate is focal (hematoxylin and eosin, ×100).](cro-0005-0238-g01){#F1}
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![Glandular epithelium of the urethra (lymphoepithelial lesion), a feature strongly suggestive of MALT lymphoma (hematoxylin and eosin, ×200).](cro-0005-0238-g03){#F3}

![Image highlights lymphoepithelial lesions; immunohistochemistry stain with cytokeratin (Dako; ×200).](cro-0005-0238-g04){#F4}

![Image highlights lymphoepithelial lesion; immunohistochemistry stain with cytokeratin (Dako; ×400).](cro-0005-0238-g05){#F5}

![Image highlights lymphoid cells with positive reaction to CD20 (Dako; ×200).](cro-0005-0238-g06){#F6}

###### 

Summary of reported cases of primary urethral lymphoma

  No.                                  First author            Year   Age years   Sex   Chief complaint                          Localization           Treatment      Outcome   Observation period
  ------------------------------------ ----------------------- ------ ----------- ----- ---------------------------------------- ---------------------- -------------- --------- --------------------
  1[\*](#T1F1){ref-type="table-fn"}    Grabstald \[[@B16]\]    1966   Unknown     F     Unknown                                  Unknown                Radiation      NED       9 months
  2[\*](#T1F1){ref-type="table-fn"}    Nabholtz \[[@B10]\]     1989   51          F     Urethral polyp                           Localized urethral     Chemo + exci   NED       120 months
  3[\*](#T1F1){ref-type="table-fn"}    Pak \[[@B11]\]          1980   83          F     Dysuria                                  Localized urethral     None           Dead      Unknown
  4[\*](#T1F1){ref-type="table-fn"}    Simpson \[[@B12]\]      1990   76          F     Urethral mass                            Localized urethral     Excision       NED       24 months
  5[\*](#T1F1){ref-type="table-fn"}    Vapnek \[[@B15]\]       1992   31          F     Irregular vaginal bleeding               Localized urethral     Chemo + radi   NED       9 months
  6[\*](#T1F1){ref-type="table-fn"}    Kakizaki \[[@B20]\]     1994   63          M     Urethral mass                            Localized urethral     Chemo + exci   NED       36 months
  7[\*](#T1F1){ref-type="table-fn"}    Ohsawa \[[@B21]\]       1994   78          F     Dysuria, polyuria                        Localized urethral     Chemotherapy   Unknown   Unknown
  8[\*](#T1F1){ref-type="table-fn"}    Khatib \[[@B2]\]        1993   65          F     Irregular vaginal bleeding               Localized urethral     Excision       NED       24 months
  9[\*](#T1F1){ref-type="table-fn"}    Atalay \[[@B19]\]       1998   76          F     Pain on urination, urinary tract tumor   Localized urethral     None           Dead      Unknown
  10                                   Kurtman \[[@B22]\]      2001   32          M     Urinary retention                        Localized urethral     Radiation      NED       15 months
  11                                   Masuda \[[@B3]\]        2002   56          M     Gross hematuria                          Localized urethral     Radiation      NED       21 months
  12                                   Inuzuka \[[@B23]\]      2003   69          F     Dysuria, urinary tract tumors            Localized urethral     Exci + chemo   NED       6 months
  13                                   Ryu \[[@B24]\]          2003   25          M     Dysuria, tumor palpable lump             Localized urethral     Chemotherapy   NED       67 months
  14                                   Chuang \[[@B25]\]       2005   50          F     Caruncle                                 Localized urethral     Radiation      NED       14.5 months
  15                                   Richter \[[@B18]\]      2007   48          M     Dysuria, meat hematuria eye              Localized urethral     Exci + chemo   NED       3 months
  16[\*](#T1F1){ref-type="table-fn"}   Melicow \[[@B9]\]       1972   76          F     Caruncle, hematuria                      Local infiltration     TUR + radi     NED       12 months
  17[\*](#T1F1){ref-type="table-fn"}   Touhami \[[@B13]\]      1987   63          F     Genital itching, dysuria                 Local infiltration     Chemotherapy   NED       48 months
  18[\*](#T1F1){ref-type="table-fn"}   Selch \[[@B14]\]        1993   75          F     Irregular vaginal bleeding               Local infiltration     Radiation      NED       42 months
  19[\*](#T1F1){ref-type="table-fn"}   Shimizu \[[@B26]\]      1997   82          F     Dysuria                                  Local infiltration     Chemo + radi   Dead      7 months
  20[\*](#T1F1){ref-type="table-fn"}   Watson \[[@B27]\]       1949   62          F     Caruncle, spotting                       Disseminated           Excision       Dead      5 months
  21[\*](#T1F1){ref-type="table-fn"}   Allen \[[@B28]\]        1978   53          F     Caruncle                                 Disseminated           Palliative     Dead      2 months
  22[\*](#T1F1){ref-type="table-fn"}   Chaitin \[[@B29]\]      1993   77          F     Genital mass, hematuria                  Disseminated           Chemotherapy   NED       9 months
  23[\*](#T1F1){ref-type="table-fn"}   Lopez \[[@B6]\]         1993   57          M     Dysuria, hematuria                       Disseminated           Chemotherapy   Dead      3 months
  24[\*](#T1F1){ref-type="table-fn"}   Rajan \[[@B30]\]        1995   57          M     Urinary retention, hematuria             Disseminated           Chemotherapy   NED       6 months
  25                                   Dell\'Atti \[[@B31]\]   2005   69          F     Dysuria, from thermal weight loss        Progressive systemic   Exci + chemo   Unknown   Unknown
  26                                   Muraoka \[[@B32]\]      2009   90          F     Dysuria                                  Localized urethral     Exci + radi    NED       14 months
  27                                   Al Zahrani              2011   30          F     Caruncle                                                        Chemotherapy   NED       

Exci = Excision; chemo = chemotherapy; TUR = transurethral resection; radi = radiation; NED = no evidence of disease.

Another hospital death.
